EQ Key Statistics, Chart & Performance
The current stock price of EQ is 1.55 USD. In the past month the price increased by 31.58%. In the past year, price increased by 59.63%.
EQ Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EQ. When comparing the yearly performance of all stocks, EQ is one of the better performing stocks in the market, outperforming 92.58% of all stocks.
EQ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EQ. No worries on liquidiy or solvency for EQ as it has an excellent financial health rating, but there are worries on the profitability.
EQ Financial Highlights
Over the last trailing twelve months EQ reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS decreased by -342.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.76% | ||
| ROE | -78.92% | ||
| Debt/Equity | 0 |
EQ Forecast & Estimates
10 analysts have analysed EQ and the average price target is 2.55 USD. This implies a price increase of 64.52% is expected in the next year compared to the current price of 1.55.
For the next year, analysts expect an EPS growth of -92.57% and a revenue growth -100% for EQ
EQ Ownership
EQ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.47 | 394.585B | ||
| AMGN | AMGEN INC | 16.37 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 16.79 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.95 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.7 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.7 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.6 | 28.432B | ||
| INCY | INCYTE CORP | 12.81 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EQ
Company Profile
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 35 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.
Company Info
EQUILLIUM INC
2223 Avenida de La Playa Ste 105
La Jolla CALIFORNIA 92037 US
CEO: Bruce D. Steel
Employees: 35
Phone: 18584125302
EQUILLIUM INC / EQ FAQ
Can you describe the business of EQUILLIUM INC?
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 35 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.
Can you provide the latest stock price for EQUILLIUM INC?
The current stock price of EQ is 1.55 USD. The price increased by 3.33% in the last trading session.
Does EQ stock pay dividends?
EQ does not pay a dividend.
What is the ChartMill rating of EQUILLIUM INC stock?
EQ has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy EQ stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EQ.
What is EQUILLIUM INC worth?
EQUILLIUM INC (EQ) has a market capitalization of 94.38M USD. This makes EQ a Micro Cap stock.
Can you provide the upcoming earnings date for EQUILLIUM INC?
EQUILLIUM INC (EQ) will report earnings on 2026-03-25, after the market close.